Fate Therapeutics (FATE) Accumulated Depreciation (2014 - 2025)

Fate Therapeutics has reported Accumulated Depreciation for 12 years, with the latest figure at $36.2 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation rose 3.09% year-over-year to $36.2 million; the trailing twelve-month figure through Dec 2025 stood at $36.2 million (up 3.09% YoY), and the FY2025 full-year result was $36.2 million, up 3.09% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $36.2 million, up from $35.1 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $47.6 million in Q4 2023, with the low at $16.9 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $33.3 million across 5 years, with a median of $35.1 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation jumped 79.31% — and 2024, when it dropped 26.23%.
• Fate Therapeutics' Accumulated Depreciation stood at $16.9 million in 2021, then jumped by 79.31% to $30.4 million in 2022, then jumped by 56.75% to $47.6 million in 2023, then slipped by 26.23% to $35.1 million in 2024, then gained by 3.09% to $36.2 million in 2025.
• The last three Accumulated Depreciation figures came in at $36.2 million (Q4 2025), $35.1 million (Q4 2024), and $47.6 million (Q4 2023), per Business Quant data.